Addendum
Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35
Report documents
-
Addendum
Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35
Dossier assessment
Indication:
Adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant or following at least two prior therapies when autologous stem cell transplant is not a treatment option
Result of dossier assessment:
Unchanged after addendum:
- Adults for whom brentuximab vedotin is the suitable therapy according to physician’s choice: hint of non-quantifiable added benefit.
- Adults for whom brentuximab vedotin is not the suitable therapy according to physician’s choice: added benefit not proven.
- Children and adolescents aged 3 years and older: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.
Project details
- Project no.
- A21-104
- Commission
- Commission awarded on 10.08.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed